Press releases

Boston Scientific Corporation (NYSE: BSX) today presented data on its 7,000- patient ARRIVE I and II registries of real-world...

Boston Scientific Corporation (NYSE: BSX) today presented data on its long- term randomized clinical trials to a special U.S....

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held November 29...

Boston Scientific Corporation (NYSE: BSX) today announced that Brenda Becker will be appointed Senior Vice President of Global Government Affairs....

Boston Scientific Corporation (NYSE: BSX) today welcomed a presentation by Joost Daemen, M.D., and Patrick Serruys, M.D., entitled...

Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's LATITUDE® 2.0...

At a meeting with analysts today, Boston Scientific Corporation (NYSE: BSX) provided its financial outlook for 2007. Sales goals for 2007 range...

Boston Scientific Corporation (NYSE: BSX) today presented a four-year update of its key randomized, controlled clinical trials (TAXUS II, IV, V and...

Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare...

Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the NexStent® Carotid Stent...

Boston Scientific Corporation (NYSE: BSX) today announced that it has received the European CE Mark for its new Artisan™ 2x8 Surgical Lead for use...

Boston Scientific Corporation (NYSE: BSX) today announced that Daniel J. Brennan has been appointed to the position of Vice President Investor...

Boston Scientific Corporation (NYSE: BSX) will simultaneously webcast the analyst meeting it is hosting on Monday, November 6. The meeting is...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of software enabling its Left Ventricular (LV) Offset feature in the Company's...

Boston Scientific Corporation (NYSE: BSX) today announced that Steven L. Zelenkofske, D.O., F.A.C.C., has been appointed Patient Safety Officer and...

Boston Scientific Corporation (NYSE: BSX) today announced 12-month follow-up data from TAXUS ATLAS, the pivotal clinical trial...

Boston Scientific Corporation (NYSE: BSX) today announced positive results from its global TAXUS OLYMPIA registry, supporting the...

Boston Scientific Corporation (NYSE: BSX) today announced that an independent meta-analysis of more than 3,500 patients from five...

Boston Scientific (NYSE: BSX) today announced two-year data from its BEACH carotid artery stenting (CAS) clinical trial. The study...

Boston Scientific Corporation (NYSE: BSX) today announced that it intends to provide lead financial support for an extension of the...

Boston Scientific Corporation (NYSE: BSX) today announced one-year results from its TC-WYRE (TAXUS® Express2™ Stent vs. Cypher Stent: What's...

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2006. Net sales for the third...

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular...

Boston Scientific Corporation (NYSE: BSX) today announced the initiation of a new clinical trial designed to identify and investigate clinically...

Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...